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Abstract 
Antipsychotics may confer long term benefits and risks, including cardiovascular disease 
(CVD) risk.  Several studies using routine clinical data have reported associations between 
antipsychotics and CVD but potential confounding and unclear classification of drug 
exposure limits their interpretation. 
Method 
We used data from The Health Improvement Network, a large UK primary care database to 
determine relative risks of (CVD) comparing similar groups of people only prescribed 
olanzapine versus either risperidone or quetiapine. We included participants over 18 
between 1995 and 2011. To assess confounding we created propensity scores for being 
prescribed each antipsychotic. We used propensity score matching and Poisson regression 
to calculate the CVD incidence rate ratios for olanzapine versus the other two drugs.  
Results 
We identified 18,319  people who received a single antipsychotic during follow-up (n=5090 
risperidone, 7797 olanzapine and 4613 quetiapine). In unmatched analyses, the CVD 
incidence rate ratio (IRR) for olanzapine versus risperidone was 0.63 (0.51-0.77) but the 
propensity score matched IRR was 0.78 (0.61-1.02). In the unmatched olanzapine versus 
quetiapine analysis the IRR adjusted for age and sex for olanzapine was 1.52 (1.16-1.98) but 
the propensity score matched analysis gave an IRR of 1.08 (0.79-1.46). 
Conclusions 
After propensity score matching, we found no statistical differences in CVD incidence 
between olanzapine and either risperidone or quetiapine. Analyses which did not account 
for confounding produced very different results. Researchers must address confounding 
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when designing observational studies to assess adverse outcomes of drugs, including 
antipsychotics.   
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Introduction 
Cardiovascular disease (CVD) mortality and morbidity is markedly elevated in people with 
severe mental illnesses such as schizophrenia, for reasons including smoking, deprivation 
and health care (Osborn et al. 2007). The contribution of antipsychotic medication to CVD 
risk and CVD mortality has generated scientific, clinical and policy-focused debate. The 
mechanism might include the cumulative adverse effects of different agents, including 
weight gain, glucose, ECG abnormalities and lipid levels. A systematic review in 2009 
concluded that antipsychotics were associated with increased CVD mortality in 
schizophrenia (Weinman et al. 2009).  However contradictory evidence has emerged in the 
past five years. Large cohort studies have been published using linked national data in 
Finland (Kiviniemi et al. 2013, Tiihonen et al. 2009), Sweden (Torniainen et al. 2014, Crump 
et al. 2014) of people with long term  or first onset schizophrenia as well as UK studies 
including all people using antipsychotics in primary care  (Murray-Thomas et al. 2013). These 
studies have shown varying results, reporting that second generation antipsychotic users 
are either more or less likely to develop from cardiovascular disease. There has been 
particular concern regarding olanzapine in terms of cardiovascular risks, including weight 
gain, and it is one of the most commonly prescribed antipsychotics in the UK and 
internationally (Weinman et al. 2009, Marston et al. 2014).  
Comparing the risk for CVD with individual antipsychotics such as olanzapine is 
methodologically challenging; it requires large studies with sufficient person years of follow-
up. Most studies addressing these questions use large routinely collected data sources, 
since bespoke trials and cohort studies of this size and length of follow-up are probably 
unfeasible. However using routine data bring major challenges. This includes the highly 
heterogeneous groups of people in the data source, often deriving from quite different time 
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periods. More historical cohorts may have poorer quality information on older exposures, 
but they often have greater statistical power by virtue of larger numbers of CVD events. 
More contemporary cohorts of younger people may provide higher quality data on 
exposures (such as smoking or drug dose), but will have fewer CVD events. The theoretical 
pathway by which antipsychotics may predispose to CVD is probably complex and lengthy. 
Different agents may affect different parts of this pathway. These effects cannot be 
differentiated unless we select “purer” cohorts exposed to single antipsychotic agents 
during follow-up. However in real life clinical setting, from which data are often derived, 
patients switch between medications, stopping and starting medications for periods of time 
(Leiberman et al. 2005). This makes it difficult to establish which agent might be associated 
with any elevated or decreased risk of CVD mortality. It is also important to carefully select 
outcomes in research using routine databases. Many studies of antipsychotic outcomes 
simply combine all causes of mortality  however this approach is unlikely to yield meaningful 
evidence when the mechanisms underlying different diseases and causes of death (such as 
suicide and CVD) are so varied (Weinman et al. 2009, De Hert et al. 2010). 
 
A further challenge with routine data is assessing the role of confounding, when estimating 
the relationship between different antipsychotics and CVD. To do this we need good quality 
data on potential confounding factors such as co-morbid physical health, diagnoses, or 
substance misuse. These variables are not available in many large observational datasets. 
We designed a study to compare risk of incident CVD in people prescribed the three most 
commonly used antipsychotic agents in the UK, olanzapine, risperidone and quetiapine. We 
aimed to address some of the aforementioned challenges when using routinely available 
clinical data. We aimed to select groups of people with who only used one of the three most 
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common antipsychotics during their follow-up and to compare their risk of incident CVD. 
We assessed  whether olanzapine confers greater risk of CVD than other second generation 
antipsychotics. We used propensity score matching to select three  groups of antipsychotic 
users who were similar in terms of  their balance of  known confounders. 
Methods  
 
Study design 
A prospective cohort study using routinely collected data in UK primary care 
Setting 
We extracted data from The Health Improvement Network (THIN) (THIN, 2015), a United 
Kingdom primary care database which derives data from routine administrative and clinical 
practice. We used data from an established cohort of THIN patients prescribed first and 
second generation antipsychotics in UK primary care (Marston et al. 2014). THIN includes 
longitudinal data from more than 12 million patients with a geographical spread that is 
generally representative of the UK general population (Blak et al. 2011). Staff at general 
practices enter data using a hierarchical system of Read codes (Chisholm 1990, Dave and 
Petersen 2009), for information such as symptoms, signs and diagnoses. THIN has been 
successfully used for a range of mental health and pharmaco-epidemiological research 
including work regarding antipsychotics, severe mental illnesses and cardiovascular disease 
(Marston et al. 2014; Hayes et al. 2016; Osborn et al. 2014).  
Participants 
The cohort included all people aged over 18 with an electronic record of being prescribed 
olanzapine, risperidone or quetiapine during follow-up, between 1995 and December 2011. 
We excluded people with pre-existing cardiovascular disease, heart failure or dementia. 
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Main exposure 
Since we aimed to identify sole users of the most common three antipsychotics, we 
excluded people who were prescribed additional first or second antipsychotics during 
follow-up, in addition to their index drug. This derived three groups of people solely 
receiving 1) olanzapine 2) risperidone or 3) quetiapine. 
Follow-up period 
Follow up commenced at first prescription of risperidone, olanzapine or quetiapine and 
ended at death, incident CVD, the patient leaving the practice or December 2011. We 
excluded those with less than 6 months follow-up data. 
 
Covariates for propensity score matching 
In order to balance the observed characteristics of the groups receiving the different 
antipsychotics, we generated propensity scores for receiving olanzapine, versus either 
risperidone or quetiapine. We created plots of propensity score distributions to visually 
compare 1) olanzapine versus risperidone sole users and 2) olanzapine versus quetiapine 
sole users. We then used propensity score matching to select groups of patients receiving 
the pairs of drugs of interest. We included people whose propensity scores overlapped 
using predefined criteria below and we excluded patients for whom we could not find an 
eligible comparison. We selected patients using 1:1 matching of propensity score, without 
replacement, but including individuals with tied scores.  Calipers for matching pairs of 
patients were set at 0.2 of a standard deviation of the propensity score as recommended by 
Austin (2011) for observational studies. 
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We calculated the propensity scores for each patient using logistic regression. We included a 
range of relevant variables in the model. These variables were selected by the research 
team, including epidemiologists, experts in primary care data, academic GPs and 
psychiatrists. We were deliberately inclusive and made use of any socio-demographic, 
biometric, diagnostic or co-prescribing variable which might plausibly influence or be 
related to the choice of olanzapine risperidone quetiapine or which might influence the CVD 
outcome.  
We included  the following variables: Mental health diagnoses (category of Severe Mental 
Illness diagnosis, namely  schizophrenia, bipolar disorder or other psychosis (Hardoon et al. 
2013)), ADHD, anxiety, depression, OCD, personality disorder, post-traumatic stress 
disorder, sleep disorders (Marston et al. 2014); chronic physical illnesses at any time 
(defined as asthma, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary 
disease (COPD), diabetes, hypertension, hypothyroid, learning disability, on the palliative 
care register); receipt of other main classes of medication at any time (antidepressants, 
diabetes medication, anti-hypertensive medication at any time, hypnotics, insulin, statin 
use); socio-demographic factors and health indicators at any time before baseline, using the 
value closest to baseline where there was more than one measurement. These included age 
at baseline, sex, Townsend quintile (The Townsend index, a widely used measure of 
geographical social deprivation; Townsend 1986) , time period when the person entered the 
cohort, high alcohol intake, illicit drug use, ethnicity, smoking status, number of  drug 
subchapters from the BNF prescribed from taken in the year before baseline, systolic blood 
pressure, height, weight, blood glucose, HbA1c, HDL cholesterol, total cholesterol); mental 
health consultations (a record of seeing a psychologist, a psychiatrist, or mental health 
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crisis). These definitions have previously been published (Marston et al. 2014; Osborn et al. 
2014).   
Main outcome 
New records of fatal or non-fatal cardiovascular disease, defined as a myocardial infarction, 
coronary heart disease, angina pectoris, major coronary surgery and revascularisation, 
cerebrovascular accident (CVA) and transient ischaemic attacks (TIA) (Osborn et al. 2014).  
 
Analysis  
Summary descriptive statistics were calculated for people who were and were not included 
in the propensity score matched groups, for each pair of antipsychotics namely olanzapine 
versus risperidone and olanzapine versus quetiapine. We then determined the number of 
CVD events occurring during follow-up for each group of matched antipsychotic users. We 
calculated incidence rate ratios for cardiovascular disease comparing sole users of 
olanzapine against 1) sole users of risperidone and 2) sole users of quetiapine, using Poisson 
regression. We performed a supplementary analysis to explore the impact of matching on 
propensity scores by calculating Incident rate ratios for the total, unmatched sample.  
Finally we performed an additional, more restricted propensity score analysis, where we 
only included medical variables which had recorded before baseline and therefore before 
the first prescription of antipsychotic, in case any of the variables within our propensity 
score might have resulted directly from the prescription of the antipsychotic. 
Analyses were carried out using Stata version 13 (StataCorp 2013). 
 
Results 
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We identified 18,319  people who were sole users of one of the three antipsychotics of 
interest, including  5909 sole users of risperidone, 7,797 sole users of olanzapine and 4613 
sole users of quetiapine. Figure one is a flow chart of people included and excluded from 
this sample.  The median follow-up period across the three groups of sole users was 2.3 
years (IQR 1.2-4.4); giving a total of 57,448 person years. The commonest additional 
prescriptions in the excluded groups were additional first generation antipsychotics during 
follow-up (n=7078; 22.3%) and also receiving an additional drug out of the three most 
common namely olanzapine, risperidone or quetiapine (n=2907; 9.2%). The mean time from 
GP registration to first prescription of each antipsychotic was risperidone 2.11 years (sd 
3.10); olanzapine 2.40 years (sd 3.37) and quetiapine 3.19 years (4.01). 
 
Olanzapine vs. risperidone 
The distribution of the propensity scores and the characteristics of olanzapine versus 
risperidone users before and after matching are shown in figure 2, Tables 1 and 2. The 
propensity score distributions in figure 2 are very different for olanzapine and risperidone 
users prior to matching. The total unmatched risperidone group was more likely to be male, 
fewer were recorded as having white ethnicity, fewer lived in deprived areas of the UK and 
fewer had one of the SMI diagnoses such as schizophrenia (table 1). However there were 
more people diagnosed with diabetes mellitus in the risperidone group, mean weight in Kg 
was higher in the risperidone group and the people receiving olanzapine were more likely to 
have had contact with secondary mental health services (table 2). 
After the propensity score matching, the groups who were users of olanzapine and 
risperidone were more similar regarding variables such as gender, diagnosis, ethnicity, co-
prescribing, weight and diabetes. (tables 1 and 2).  
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Olanzapine vs. quetiapine 
The unmatched groups of sole users of olanzapine and quetiapine were also different in 
terms of their propensity score distributions (figure 2), as well as the individual variables 
contributing to the propensity score (tables 1 and 2). People receiving only quetiapine 
during their follow-up were more likely to be male, white, and less likely to have a SMI 
diagnosis including schizophrenia, compared to those receiving olanzapine (table 1). 
However they were more likely to have a diagnosis of diabetes and to be in receipt of anti-
diabetic or anti-hypertensive medication (table 2). After the propensity score matching, the 
two groups were far more similar in terms of their baseline characteristics. 
Relative incidence rates of cardiovascular events  
Head to head comparisons of individual antipsychotic agents  
The propensity score matching exercise resulted in 4557 olanzapine sole users and 4753 
risperidone sole users with 15,805 and 16,171 years of follow-up respectively. The numbers 
developing a CVD event were 100 (2.2%) for olanzapine and 132 (2.8%) for risperidone. The 
incidence rate ratio (IRR) for CVD in olanzapine compared to risperidone was 0.78 (0.60-
1.01) (table 3). In the supplementary analysis using the unmatched sample, the unadjusted 
IRR suggested that CVD rates were significantly lower in the olanzapine users compared to 
risperidone users (model 2; table 3), however this association within the unmatched sample 
disappeared after adjusting for age, sex and deprivation (model 3 , table 3).  
The additional propensity score matching exercise, only including variables recorded before 
baseline, resulted in fewer people being included in each antipsychotic group 
(supplementary tables 1- 2 and supplementary figure). However there was still no difference 
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in CVD incidence between the two olanzapine and risperidone (IRR 1.07; 0.78-1.45) 
supplementary table 3). 
 
 In the olanzapine versus quetiapine analysis, there were 3789 olanzapine sole users, with 
10,323 years of follow-up eligible for comparison with the 4133 quetiapine sole users with 
10,601 years follow-up. The numbers developing a CVD event were 81 (2.1%) and 82 (2.0%) 
respectively. After accounting for person years of follow-up, the incidence rate ratio for CVD 
in olanzapine users (compared to quetiapine users) was 0.96 (0.71-1.31). In the 
supplementary analysis using the unmatched sample, the unadjusted IRR also showed no 
significant differences in CVD rates between the olanzapine users and quetiapine users 
(model 2; table 3). However when this unmatched IRR was adjusted for age, sex and 
deprivation, the olanzapine users were significantly more likely to develop CVD (IRR 1.52 
1.16 to 1.98 ; model 3, table 3). 
The additional propensity score matching exercise, again resulted in fewer people being 
included in each antipsychotic group (supplementary tables 1- 2). However there was still no 
difference in CVD incidence between the olanzapine and quetiapine  (IRR 0.90; 0.62-1.30) 
supplementary table 3). 
 
 
Discussion 
This large study aimed to address methodological criticisms of previous studies reporting 
the risks of CVD with antipsychotics (De Hert et al. 2010). When we included a large number 
of variables to create  propensity scores, and matched by these scores,  we found no 
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significant differences in rates of cardiovascular disease when comparing sole users of 
olanzapine with sole users of either risperidone or quetiapine.   
We used routinely collected primary care data and endeavoured to address some of the 
problems inherent to these types of data.  We found evidence that people receiving these 
three individual drugs differed considerably at baseline, in terms of very important variables 
such as gender, ethnicity, and key cardiovascular risk factors such as weight and diabetes. 
Perhaps surprisingly, those prescribed olanzapine had lower weight and lower rates of 
diabetes and obesity, which could lead to erroneous results if not accounted for.  Through 
propensity score matching, we identified groups who were similar in terms of these 
characteristics. We derived sample sizes of three to four thousand people solely prescribed 
each drug, with between 10 and 15 thousand person years of follow-up for each drug, and 
did not find different rates of cardiovascular disease. In our study we sought to make our 
groups as similar as possible in terms of the variables we assessed, however some residual 
confounding is likely to still be present (Freemantle et al, 2013). For instance the severity of 
the diseases for which the drugs are prescribed may be different, as well as the associated 
level of impairment, which might influence CVD risk.   
Our study identified more CVD events for each individual antipsychotic agent than many of 
the recent antipsychotic mortality cohort studies which have reported that antipsychotics 
are harmful or beneficial in relation to all-cause mortality, or in terms of suicide and in 
terms of CVD mortality (Murray Thomas et al. 2013;  Kiviniemi et al. 2013). THIN also offers 
more information regarding possible confounding variables, compared to studies based on 
national linked samples such as the large Scandinavian databases. Our work demonstrates 
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the challenges of designing studies to assess long term associations between medications 
used for long term mental health conditions and events such as CVD.  
The methodological strengths of our study include restricting the exposed samples to 
people who only received one individual antipsychotic of interest during their follow-up, 
and the propensity score matching to account for known confounders. This allowed head to 
head comparisons of sole users, which has rarely been done in previous studies; many 
researchers group antipsychotic drugs by class or simply look at people exposed and 
unexposed to any antipsychotic. An exception is Crump et al. (2014), who divided 
antipsychotic users into subgroups of ‘any use’ and ‘sole use’. However their analysis was 
also limited by small numbers of CVD deaths in their large Swedish cohort, and they only 
report all-cause (not CVD) mortality for each individual antipsychotic agent.  
Limitations 
All routine databases have limitations in terms of missing data on covariates, lack of 
information regarding prescriptions outside follow-up time, and in our case, lack of data 
regarding prescriptions in secondary care. However in the UK most people are registered 
with a general practitioner (Lis and Mann, 1995) and most prescribing for long term 
conditions is performed by general practitioners (Prah et al. 2007) . An exception is 
clozapine which is mainly prescribed by psychiatric outpatient clinics- so we did not aim to 
assess CVD risk in people receiving this medication. The selection of sole users is 
methodologically pure, but in reality many people switch between agents over time 
(Lieberman et al. 2005). The effects of switching between different agents and CVD 
outcomes would be hard to study and are not be addressed by our study design.  
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Since we did not find associations between the individual antipsychotics of interest and 
CVD, there was no reason to assess subdivisions of exposure such as high and low doses, 
length of exposure or any interaction between medications and diagnosis. However these 
subdivisions would not have been possible given the number of CVD events, and this is a 
lesson for future research studies- they need to be extremely large to look at dose effects of 
individual agents or to explore specific subtypes of CVD such as coronary heart disease or  
stroke. Because our sample are matched on propensity scores, we cannot provide estimates 
of CVD incidence according to the variables within those propensity scores, such as age or 
diagnosis. 
We recommend that future cohort studies of antipsychotics should carefully assess issues of 
confounding, using propensity score matching or other applicable methods, but must still 
recognise that it may be impossible to adjust for unmeasured confounders, such as the 
clinical reasons why a certain drug may be chosen for certain individuals. For the last two 
decades, clinicians and patients have been warned of the potential for weight gain, 
particularly with olanzapine (de Hert et al,  2010). Our results suggest that people receiving 
this drug in real life are less likely to be overweight or have diabetes, which perhaps 
indicates a deliberate avoidance of the drug in people at risk of these conditions. However, 
this means that any studies of longer term outcomes must control for the baseline 
differences in people receiving these agents, or results regarding risks and benefits of 
antipsychotics may be biased and inaccurate. 
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Table 1: Characteristics of people prescribed three antipsychotics as monotherapy, before and after propensity score matching 
 
 Total before matching Olanzapine versus Risperidone after 
propensity score matching 
Olanzapine versus Quetiapine after 
propensity score matching 
 Olanzapine 
(N=7797) 
Risperidone 
(N=5909) 
Quetiapine 
(N=4613) 
Olanzapine 
(N=4557) 
Risperidone 
(N=4753) 
Olanzapine 
(N=3789) 
Quetiapine 
(N=4133) 
 n % n %  n % n % n % n % n % 
Sociodemographic               
Male 4436 57 3112 53 1869 41 2422 53 2574 54 1586 42 1774 43 
Age mean (SD) 42 (16) 47 (22) 45 (19) 45 (18) 45 (20) 45 (17) 45 (19) 
               
White 3206 41 2096 35 2459 53 1653 36 1761 37 1954 52 2164 52 
Black 231 3 151 3 61 1 100 2 141 3 91 2 58 1 
South Asian 110 1 75 1 54 1 62 1 67 1 58 2 50 1 
Other 203 3 127 2 77 2 98 2 114 2 107 3 66 2 
Missing 4047 52 3460 59 1962 43 2644 58 2670 56 1579 42 1795 43 
               
Least deprived 1013 13 922 16 709 15 697 15 686 14 580 15 629 15 
2 1024 13 915 15 701 15 634 14 665 14 581 15 624 15 
3 1448 19 1185 20 902 20 884 19 920 19 731 19 805 19 
4 1954 25 1350 23 1106 24 1094 24 1121 24 894 24 1004 24 
Most deprived 1993 26 1319 22 988 21 1034 23 1177 25 848 22 888 21 
Missing 365 5 218 4 207 4 214 5 184 4 155 4 183 4 
               
Diagnosis*               
Schizophrenia 1799 23 1120 19 432 9 788 17 1081 23 428 11 425 10 
Bipolar 987 13 331 6 693 15 492 11 313 7 415 11 660 16 
Other psychoses 1278 16 749 13 379 8 736 16 691 15 547 14 361 9 
SMI register only 399 5 305 5 165 4 266 6 248 5 148 4 154 4 
No SMI diagnosis* 3334 43 3404 58 2944 64 2275 50 2420 51 2251 59 2533 61 
               
ADHD 42 0.5 135 2 41 1 41 1 39 1 31 1 35 1 
Anxiety 1245 16 863 15 1246 27 750 16 769 16 947 25 1030 25 
Depression 2158 28 1463 25 2041 44 1256 28 1323 28 1578 42 1720 42 
OCD 130 2 128 2 121 3 104 2 105 2 93 2 97 2 
Personality disorder 341 4 215 4 341 7 173 4 193 4 250 7 288 7 
PTSD 158 2 58 1 134 3 39 1 57 1 110 3 120 3 
Sleep disorder 697 9 531 9 678 15 423 9 427 9 525 14 560 14 
No diagnosis 752 10 1414 24 561 12 695 15 765 16 395 10 517 13 
*This includes those with no diagnosis  
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Table 2. Clinical characteristics of people prescribed three antipsychotics as monotherapy, before and after propensity score 
matching 
 
 Total Olanzapine versus Risperidone after 
propensity score matching 
Olanzapine versus Quetiapine after 
propensity score matching 
 Olanzapine 
(N=7797) 
Risperidone 
(N=5909) 
Quetiapine 
(N=4613) 
Olanzapine 
(N=4557) 
Risperidone 
(N=4753) 
Olanzapine 
(N=3789) 
Quetiapine 
(N=4133) 
 n % n % Quet n % n % n % n % n % 
Conditions               
Asthma 1179 15 813 14 913 20 678 15 703 15 715 19 797 19 
Atrial Fibrillation 59 1 107 2 76 2 58 1 52 1 47 1 65 2 
CKD 274 4 238 4 222 5 188 4 183 4 174 5 192 5 
COPD 178 2 140 2 103 2 124 3 122 3 92 2 90 2 
Diabetes 459 6 550 9 429 9 369 8 377 8 316 8 350 8 
Hypertension 795 10 700 12 621 13 524 12 550 12 479 13 530 13 
Hypothyroidism 372 5 321 5 312 7 253 6 253 5 249 7 274 7 
Learning disability 276 4 823 14 108 2 276 6 304 6 99 3 106 3 
Palliative care register 65 1 58 1 40 1 46 1 46 1 28 1 39 1 
               
Prescribed drugs               
Antidepressants 5599 72 3722 63 3756 81 3046 67 3236 68 3093 82 3322 80 
Antidiabetics 291 4 364 6 290 6 239 5 246 5 214 6 227 5 
Antihypertensives 1744 22 1392 24 1413 31 1067 23 1124 24 1082 29 1201 29 
Hypnotics 3197 41 2109 36 2361 51 1692 37 1788 38 1892 50 2041 49 
Insulin 61 1 145 2 96 2 61 1 68 1 51 1 69 2 
Statins 909 12 634 11 620 13 473 10 541 11 474 13 534 13 
               
Health indicators (any time 
before start) 
              
High alcohol consumption 564 7 296 5 361 8 244 5 286 6 297 8 318 8 
Illicit drug taking 1184 15 542 9 577 13 461 10 533 11 481 13 539 13 
               
Non-smoker 259 3 241 4 142 3 203 4 170 4 131 3 122 3 
Ex-smoker 3073 39 2469 42 2286 50 1874 41 1986 42 1829 48 1980 48 
Current smoker 2837 36 1530 26 1538 33 1363 30 1439 30 1259 33 1414 34 
missing 1628 21 1669 28 647 14 1117 25 1158 24 570 15 617 15 
               
Systolic BP mean (SD) 124 (17) 126 (18) 125 (17) 126 (18) 125 (18) 125 (17) 125 (17) 
Fasting glucose mmol/L mean 
(SD) 
5.3 (1.7) 5.8 (2.4) 5.4 (2.1) 5.6 (1.9) 5.7 (2.0) 5.3 (1.7) 5.3 (1.7) 
HbA1c mmol/mol mean (SD) 48 (21) 54 (21) 51 (20) 50 (20) 52 (21) 49 (20) 49 (19) 
Total cholesterol mmol/L mean 5.32 (1.17) 5.14 (1.18) 5.27 (1.18) 5.25 (1.15) 5.17 (1.18) 5.27 (1.13) 5.29 (1.18) 
 20 
 
(SD) 
 
HDL cholesterol mmol/L mean 
(SD) 
1.41 (0.49) 1.39 (0.76) 1.38 (0.43) 1.43 (0.53) 1.39 (0.80) 1.43 (0.51) 1.38 (0.43) 
Weight kg mean (SD) 73 (18) 75 (19) 76 (20) 74 (18) 75 (19) 74 (19) 76 (20) 
Height m mean (SD) 1.70 (0.10) 1.68 (0.11) 1.68 (0.10) 1.69 (0.10) 1.69 (0.11) 1.68 (0.10) 1.68 (0.10) 
               
Seen a psychologist at least 
once 
1141 15 705 12 864 19 570 13 616 13 671 18 752 18 
Seen a psychiatrist at least once 6246 80 3883 66 3608 78 3187 70 3416 72 3005 79 3247 79 
Had at least one crisis not MHA 117 2 56 1 73 2 54 1 56 1 63 2 62 2 
Had at least one crisis MHA 616 8 287 5 323 7 208 5 271 6 270 7 296 7 
 
 
BP Blood Pressure. CKD: Chronic Kidney Disease. COPD: Chronic Obstructive Pulmonary Disease. HDL High Density Lipoprotein MHA. Mental Health Act Assessment. SD 
Standard Deviation.  
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Table 3 Results from matched and unmatched analysis comparing CVD in three 
antipsychotics 
 
Olanzapine versus Risperidone 
 Main Matched analysis Supplementary unmatched analyses 
  Model 1 Model 2 Model 3 
 IRR (95% CI) IRR (95% CI) IRR (95% CI) 
CVD incidence       
Olanzapine n/N 
% 
100/4557 2.19 166/7797 2.13 166/7797 2.13 
Risperidone n/N 
% 
132/4753 2.78 202/5909 3.42 202/5909 3.42 
       
Olanzapine 0.79 (0.61, 1.02) 0.63 (0.51, 0.77) 0.99 (0.80, 1.23) 
Risperidone 
(reference) 
1.0  1.0  1.0   
Female     0.82 (0.66, 1.02) 
Age     1.05 (1.05, 1.06) 
       
Townsend 
Quintiles 
      
1 least deprived 
(Reference) 
    1.0   
2     1.00 (0.70, 1.44) 
3     1.21 (0.86, 1.71) 
4      1.25 (0.89, 1.75) 
5 most deprived     1.45 (1.02, 2.07) 
Missing     1.64 (0.97, 2.76) 
 Olanzapine versus Quetiapine 
 Main matched analysis Supplementary unmatched analyses 
 Model 1 Model 2 Model 3 
 IRR (95% CI) IRR (95% CI) IRR (95% CI) 
CVD incidence       
Olanzapine n/N 
% 
81/3789 2.14 166/7797 2.13 166/7797 2.13 
Quetiapine n/N % 82/4133 1.98 90/4613 1.95 90/4613 1.95 
       
Olanzapine 1.08 (0.79,1.46) 1.10 (0.85, 1.42) 1.52 (1.16, 1.98) 
Quetiapine 
(Reference) 
1.0  1.0  1.0  
       
Female     0.73 (0.56, 0.94) 
Age     1.06 (1.05, 1.06) 
       
Townsend 
Quintiles 
      
1 least deprived 
(Reference) 
    1.0  
2     0.96 (0.62, 1.49) 
3     1.09 (0.72, 1.65) 
4      1.18 (0.79, 1.76) 
5 most deprived     1.25 (0.82, 1.91) 
Missing     1.38 (0.75, 2.54) 
Model 1 Propensity score matched 
Model 2 Unadjusted unmatched analysis 
Model 3 Unmatched analysis, adjusted for age sex and deprivation 
 
IRR: Incidence rate ratio 
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Figure 1. Flow of Participants 
 
R Risperidone O Olanzapine Q Quetiapine CVD Cardiovascular Disease
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Figure 2. Propensity scores for being prescribed individual antipsychotics, before and after 
propensity score matching 
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Supplementary propensity score analysis. Restricting propensity scores to only include variables recorded pre-baseline. 
Supplementary Table 1: Characteristics of people prescribed three antipsychotics as monotherapy before & after propensity score 
matching 
 Total before matching Olanzapine versus Risperidone after 
propensity score matching 
Olanzapine versus Quetiapine after 
propensity score matching 
 Olanzapine 
(N=7797) 
Risperidone 
(N=5909) 
Quetiapine 
(N=4613) 
Olanzapine 
(N=3049) 
Risperidone 
(N=3212) 
Olanzapine 
(N=2823) 
Quetiapine 
(N=3127) 
 n % n % n % n % n % n % n % 
Sociodemographic               
Male 4436 57 3112 53 1869 41 1535 50 1634 51 1135 40 1288 41 
Age mean (SD) 42 (16) 47 (22) 45 (19) 45 (18) 45 (20) 45 (17) 45 (19) 
               
White 3206 41 2096 35 2459 53 1028 34 1095 34 1363 48 1528 49 
Black 231 3 151 3 61 1 66 2 779 2 63 2 39 1 
South Asian 110 1 75 1 54 1 41 1 44 1 36 1 30 1 
Other 203 3 127 2 77 2 51 2 80 2 82 3 47 2 
Missing 4047 52 3460 59 1962 43 1863 61 1914 60 1279 45 1483 47 
               
Least deprived 1013 13 922 16 709 15 464 15 484 15 434 15 520 17 
2 1024 13 915 15 701 15 456 15 487 15 453 16 459 15 
3 1448 19 1185 20 902 20 578 19 625 19 544 19 599 19 
4 1954 25 1350 23 1106 24 710 23 704 22 642 23 738 24 
Most deprived 1993 26 1319 22 988 21 708 23 780 24 640 23 676 22 
Missing 365 5 218 4 207 4 133 4 132 4 110 4 135 4 
               
Diagnosis*               
Schizophrenia 1799 23 1120 19 432 9 424 14 550 17 235 8 219 7 
Bipolar 987 13 331 6 693 15 340 11 197 6 278 10 488 16 
Other psychoses 1278 16 749 13 379 8 420 14 463 14 381 14 250 8 
SMI register only 399 5 305 5 165 4 188 6 195 6 126 4 124 4 
No SMI diagnosis* 3334 43 3404 58 2944 64 1677 55 1807 56 1803 64 2046 65 
               
ADHD 42 0.5 135 2 41 1 29 1 34 1 23 1 29 1 
Anxiety 1245 16 863 15 1246 27 594 19 631 20 793 28 889 28 
Depression 2158 28 1463 25 2041 44 987 32 1072 33 1303 46 1457 47 
OCD 130 2 128 2 121 3 82 3 86 3 67 2 86 3 
Personality disorder 341 4 215 4 341 7 130 4 143 4 183 6 207 7 
PTSD 158 2 58 1 134 3 39 1 44 1 86 3 94 3 
Sleep disorder 697 9 531 9 678 15 373 12 395 12 443 16 498 16 
No diagnosis 752 10 1414 24 561 12 443 15 463 14 288 10 367 12 
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*This includes those with no recorded diagnosis  
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Supplementary Table 2. Clinical characteristics of people prescribed three antipsychotics as monotherapy, before and after 
propensity score matching 
 
 Total Olanzapine versus Risperidone after 
propensity score matching 
Olanzapine versus Quetiapine after 
propensity score matching 
 Olanzapine 
(N=7797) 
Risperidone 
(N=5909) 
Quetiapine 
(N=4613) 
Olanzapine 
(N=3049) 
Risperidone 
(N=3212) 
Olanzapine 
(N=2823) 
Quetiapine 
(N=3127) 
 n % n % n % n % n % n % n % 
Conditions               
Asthma 991 13 670 11 826 18 412 14 446 14 525 19 579 19 
Atrial Fibrillation 29 0.4 68 1 55 1 22 1 24 1 19 1 24 1 
CKD 78 1 70 1 118 3 40 1 44 1 57 2 72 2 
COPD 94 1 72 1 64 1 44 1 52 2 45 2 45 1 
Diabetes 192 2 327 6 298 6 130 4 138 4 118 4 170 5 
Hypertension 508 7 508 9 505 11 290 10 304 9 291 10 342 11 
Hypothyroidism 240 3 231 4 240 5 130 4 136 4 134 5 149 5 
Learning disability 177 2 554 9 80 2 108 4 123 4 43 2 42 1 
Palliative care register 11 0.1 7 0.1 8 0.2 4 0.1 6 0.2 6 0.2 6 0.2 
               
Prescribed drugs               
Antidepressants 4933 63 3149 53 3494 76 2047 67 2188 68 2325 82 2553 82 
Antidiabetics 122 2 223 4 190 4 83 3 90 3 74 3 108 3 
Antihypertensives 1117 14 976 17 1107 24 588 19 625 19 696 25 783 25 
Hypnotics 2358 30 1509 26 1923 42 1039 34 1091 34 1302 46 1445 46 
Insulin 35 0.5 105 2 69 2 30 1 35 1 24 1 42 1 
Statins 350 4 306 5 392 9 164 5 181 6 198 7 244 8 
               
Health indicators (any time 
before start) 
              
High alcohol consumption 564 7 296 5 361 8 188 6 204 6 222 8 245 8 
Illicit drug taking 1184 15 542 9 577 13 285 9 333 10 382 14 408 13 
               
Non-smoker 259 3 241 4 142 3 167 5 156 5 119 4 116 4 
Ex-smoker 3073 39 2469 42 2286 50 1383 45 1515 47 1480 52 1656 53 
Current smoker 2837 36 1530 26 1538 33 996 33 1027 32 994 35 1103 35 
missing 1628 21 1669 28 647 14 503 17 514 16 230 8 252 8 
               
Systolic BP mean (SD) 124 (17) 126 (18) 125 (17) 126 (18) 125 (18) 125 (17) 125 (17) 
Fasting glucose mmol/L mean 
(SD) 
5.3 (1.7) 5.8 (2.4) 5.4 (2.1) 5.7 (2.3) 5.6 (1.9) 5.4 (1.7) 5.4 (2.2) 
HbA1c mmol/mol mean (SD) 48 (21) 54 (21) 51 (20) 51 (22) 51 (20) 50 (21) 50 (20) 
Total cholesterol mmol/L mean 5.32 (1.17) 5.14 (1.18) 5.27 (1.18) 5.30 (1.16) 5.20 (1.19) 5.31 (1.14) 5.29 (1.16) 
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(SD) 
 
HDL cholesterol mmol/L mean 
(SD) 
1.41 (0.49) 1.39 (0.76) 1.38 (0.43) 1.43 (0.53) 1.39 (0.81) 1.43 (0.50) 1.39 (0.42) 
Weight kg mean (SD) 73 (18) 75 (19) 76 (20) 74 (18) 75 (19) 73 (19) 76 (19) 
Height m mean (SD) 1.70 (0.10) 1.68 (0.11) 1.68 (0.10) 1.69 (0.10) 1.68 (0.11) 1.68 (0.10) 1.68 (0.10) 
               
Seen a psychologist at least 
once 
1141 15 705 12 864 19 439 14 465 14 551 20 616 20 
Seen a psychiatrist at least once 6246 80 3883 66 3608 78 2151 71 2330 73 2255 80 2479 79 
Had at least one crisis not MHA 117 2 56 1 73 2 47 2 46 1 45 2 51 2 
Had at least one crisis MHA 616 8 287 5 323 7 155 5 179 6 215 8 237 8 
BP Blood Pressure. CKD: Chronic Kidney Disease. COPD: Chronic Obstructive Pulmonary Disease. HDL High Density Lipoprotein MHA. Mental Health Act Assessment. SD 
Standard Deviation.  
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Supplementary Table 3. Results from matched and unmatched analysis comparing 
CVD in three antipsychotics 
 
Olanzapine versus Risperidone 
 Main Matched analysis Supplementary unmatched analyses 
  Model 1 Model 2 Model 3 
 IRR (95% CI) IRR (95% CI) IRR (95% CI) 
CVD incidence       
Olanzapine n/N 
% 
82/3049 2.69 166/7797 2.13 166/7797 2.13 
Risperidone n/N 
% 
81/3212 2.52 202/5909 3.42 202/5909 3.42 
       
Olanzapine 1.07 (0.78, 1.45) 0.63 (0.51, 0.77) 0.99 (0.80, 1.23) 
Risperidone 
(reference) 
1.00  1.00  1.00  
Female     0.82 (0.66, 1.02) 
Age     1.05 (1.05, 1.06) 
       
Townsend 
Quintiles 
      
1 least deprived 
(Reference) 
    1.00  
2     1.00 (0.70, 1.44) 
3     1.21 (0.86, 1.71) 
4      1.25 (0.89, 1.75) 
5 most deprived     1.45 (1.02, 2.07) 
Missing     1.64 (0.97, 2.76) 
Olanzapine versus Quetiapine 
 Main matched analysis Supplementary unmatched analyses 
 Model 1 Model 2 Model 3 
 IRR (95% CI) IRR (95% CI) IRR (95% CI) 
CVD incidence       
Olanzapine n/N 
% 
53/2823 1.88 166/7797 2.13 166/7797 2.13 
Quetiapine n/N % 65/3127 2.08 90/4613 1.95 90/4613 1.95 
       
Olanzapine 0.90 (0.62, 1.30) 1.10 (0.85, 1.42) 1.52 (1.16, 1.98) 
Quetiapine 
(Reference) 
1.00  1.00  1.00  
       
Female     0.73 (0.56, 0.94) 
Age     1.06 (1.05, 1.06) 
       
Townsend 
Quintiles 
      
1 least deprived 
(Reference) 
    1.00  
2     0.96 (0.62, 1.49) 
3     1.09 (0.72, 1.65) 
4      1.18 (0.79, 1.76) 
5 most deprived     1.25 (0.82, 1.91) 
Missing     1.38 (0.75, 2.54) 
 
Model 1 Propensity score matched 
Model 2 Unadjusted unmatched analysis 
Model 3 Unmatched analysis, adjusted for age sex and deprivation 
 
IRR: Incidence rate ratio 
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Supplementary figure 1: Propensity score analysis 
 
